MGMT and glioblastoma: Lomustine, which is administered at 80–110 mg/m2 every 6 weeks, has demonstrated clinical efficacy in recurrent GBM, with trials reporting median overall survival ranging from 8.6 to 9.8 months, particularly in patients with MGMT-methylated GBM (Wirsching et al. 2014; Weller et al. 2023).